For several years since its introduction gemcitabine monotherapy was the standard palliative treatment for this disease. Gemcitabine was approved based on a combined benefit of symptom palliation and survival, though its survival prolongation benefit is modest at best. Read more . . .
Metastatic pancreatic cancer remains one of the most lethal diseases with 5-year survival in the low single digits.